Zonegran zonisamide regulatory update

Eisai said the European Commission approved a label extension for Zonegran zonisamide from Eisai to include monotherapy in newly diagnosed epilepsy patients with partial seizures, with and without second generalization. Separately, Eisai said EMA accepted for review an application to extend the label of Zonegran as an adjunctive therapy in the treatment of partial seizures with or without generalization in adults with epilepsy to include children >=6 years. Dainippon markets the anticonvulsant that blocks sodium (Na) and calcium (Ca) channels as Excegran in Japan. ...